《新股消息》據報微泰醫療器械啟動預路演擬籌3億美元 騰訊(00700.HK)參投
據《路透》旗下IFR引述消息人宜指,微泰醫療器械已開始啟動香港IPO的預路演工作,預計籌資約3億美元。保薦人為中金及高盛。
微泰醫療已於近日通過聯交所上市聆訊,據初步招股資料,該公司專注於糖尿病管理相關研發,主要產品線包括貼敷式胰島素泵、持續血糖監測系統、閉環人工胰腺及體外診斷醫療器械設備等,其中核心產品Equil貼敷式胰島素泵已於2017年取得中國藥監局成人使用上市批准。公司表示,正尋求擴大Equil的適應症,以供兒童及青少年使用。
股權架構顯示,禮來亞洲基金、啟明創投、風投基金江蘇疌泉、泰康保險集團旗下泰康乾貞、國方資本旗下上海奏臻、中金、光大控股(00165.HK)以及騰訊(00700.HK)均為微泰醫療的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.